Michael M. Tarnow's most recent trade in Xenon Pharmaceuticals Inc was a trade of 5,144 Common Shares done at an average price of $3.7 . Disclosure was reported to the exchange on May 18, 2021.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Xenon Pharmaceuticals Inc | Michael M. Tarnow | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.67 per share. | 18 May 2021 | 5,144 | 77,942 (0%) | 0% | 3.7 | 18,878 | Common Shares |
| Xenon Pharmaceuticals Inc | Michael M. Tarnow | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2021 | 5,144 | 0 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharmaceuticals Inc | Michael M. Tarnow | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2021 | 2,057 | 0 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharmaceuticals Inc | Michael M. Tarnow | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.87 per share. | 18 May 2021 | 2,057 | 71,770 (0%) | 0% | 3.9 | 7,961 | Common Shares |
| Xenon Pharmaceuticals Inc | Michael M. Tarnow | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2021 | 1,028 | 0 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharmaceuticals Inc | Michael M. Tarnow | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.67 per share. | 18 May 2021 | 1,028 | 72,798 (0%) | 0% | 3.7 | 3,773 | Common Shares |
| Xenon Pharmaceuticals Inc | Michael M. Tarnow | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 28 Oct 2020 | 10,288 | 69,713 (0%) | 0% | 0 | Common Shares | |
| Xenon Pharmaceuticals Inc | Michael M. Tarnow | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.76 per share. | 28 Oct 2020 | 5,144 | 80,001 (0%) | 0% | 3.8 | 19,341 | Common Shares |
| Xenon Pharmaceuticals Inc | Michael M. Tarnow | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Oct 2020 | 5,144 | 0 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharmaceuticals Inc | Michael M. Tarnow | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Oct 2020 | 5,144 | 0 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharmaceuticals Inc | Michael M. Tarnow | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.76 per share. | 28 Oct 2020 | 5,144 | 74,857 (0%) | 0% | 3.8 | 19,341 | Common Shares |